Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Conditions: Metastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Cancer; Soft Tissue Sarcoma Interventions: Drug: Surufatinib and Tislelizumab _ Part 1; Drug: Surufatinib and Tislelizumab _ Part 2 Sponsors: Hutchison Medipharma Limited; BeiGene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials